Director, Duke Prostate Center
Division Chief, Urology

Department / Division:
Surgery / Urology

Address:
DUMC 3707
Durham, NC 27710

Appointment Telephone:
919-668-8108

Office Telephone:
919-684-5057

Fax Telephone:
919-684-8794

• MD, Jefferson Medical College of Thomas Jefferson University (Pennsylvania), 1982

• Surgery, Walter Reed Army Medical Center (Washington, DC), 1982-1983
• Urology, Walter Reed Army Medical Center (Washington, DC), 1983-1987

• Urologic Oncology, Duke University Medical Center, 1988-1989

• Fellow, American College of Surgeons

Clinical Interests:
Minimally invasive nerve-sparing radical prostatectomy, treatment of PSA-only or biochemical recurrence of prostate cancer, prostate cancer in African Americans, multi-disciplinary management of prostate cancer, clinical trials in prostate disease, early-stage testicular cancer, prostate cancer and outcomes/database research

Representative Publications:
Xu DD, Sun SD, Wang F, Sun L, Stackhouse D, Polascik T, Albala DM, Moul JW, Caire A, Robertson CN. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology. 2009 Sep;74(3):654-8. (2009) Abstract

Uhlman MA, Sun L, Stackhouse DA, Caire AA, Polascik TJ, Robertson CN, Madden J, Vollmer R, Albala DM, Moul JW. Tumor Volume, Tumor Percentage Involvement, or Prostate Volume: Which Is Predictive of Prostate-specific Antigen Recurrence? Urology. 2009 Oct 10. (2009) Abstract

Tsivian M, Sun L, Mouraviev V, Madden JF, Mayes JM, Moul JW, Polascik TJ. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology. 2009 Nov;74(5):1090-3. (2009) Abstract

Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol. 2009 Nov;182(5):2242-8. (2009) Abstract

Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, Robertson CN, Albala DM, Polascik TJ, Donatucci CF, Maloney KE, Moul JW. Factors predicting prostatic biopsy Gleason sum under grading. J Urol. 2009 Jul;182(1):118-22; discussion 123-4. (2009) Abstract

Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW, Mouraviev V. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer. 2009 May 15;115(10):2104-10. (2009) Abstract

Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D'Amico AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):659-64. (2009) Abstract

Moul JW. Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example. Eur Urol. 2009 Jun;55(6):1266-8. (2009) Abstract

Moul JW. Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU Int. 2009 Jan;103(2):145-6. (2009) Abstract

Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer. 2009 Aug 1;115(15):3376-8. (2009) Abstract

Moul JW. Report from Durham. Prostate Cancer Prostatic Dis. 2009;12(3):209-10. (2009) Abstract

Moul JW. Post-radical prostatectomy management options for positive surgical margins: argument for observation. Urol Oncol. 2009 Jan-Feb;27(1):92-6. (2009) Abstract

Moul JW. Innovations in urology from military medicine. Urol Oncol. 2009 Sep-Oct;27(5):551-2. (2009) Abstract

Moul JW, Tang P, Sun L. Editorial Comment on: Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. Eur Urol. 2009 Mar 13. (2009) Abstract

Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ. Prostate cancer: the new landscape. Curr Opin Urol. 2009 Mar;19(2):154-60. (2009) Abstract

Jayachandran J, Schroeck F, Sun L, Gerber L, Moreira DM, Moul JW, Freedland SJ. The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database. BJU Int. 2009 Aug 25. (2009) Abstract

Habib AS, Polascik TJ, Weizer AZ, White WD, Moul JW, ElGasim MA, Gan TJ. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. Anesth Analg. 2009 Jun;108(6):1950-3. (2009) Abstract

Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009;12(3):259-63. (2009) Abstract

Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol. 2009 Oct 15. (2009) Abstract

D'Alonzo RC, Gan TJ, Moul JW, Albala DM, Polascik TJ, Robertson CN, Sun L, Dahm P, Habib AS. A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. J Clin Anesth. 2009 Aug;21(5):322-8. (2009) Abstract

Chino J, Schroeck FR, Sun L, Lee WR, Albala DM, Moul JW, Koontz BF. Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy. BJU Int. 2009 Nov;104(10):1496-500. (2009) Abstract

Chen VH, Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. Technol Cancer Res Treat. 2009 Apr;8(2):99-104. (2009) Abstract

Caire AA, Sun L, Robertson CN, Polascik TJ, Maloney KE, George DJ, Price MM, Stackhouse DA, Lack BD, Albala DM, Moul JW. Public Survey and Survival Data Do Not Support Recommendations to Discontinue Prostate-specific Antigen Screening in Men at Age 75. Urology. 2009 Oct 6. (2009) Abstract

Caire AA, Sun L, Ode O, Stackhouse DA, Maloney K, Donatucci C, Mouraviev V, Polascik TJ, Robertson CN, Albala DM, Moul JW. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology. 2009 Sep;74(3):643-7. (2009) Abstract

Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009 Aug;182(2):491-6; discussion 496-8. (2009) Abstract

Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int. 2009 Aug;104(3):310-4. (2009) Abstract

Whittemore DE, Hick EJ, Carter MR, Moul JW, Miranda-Sousa AJ, Sexton WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.  J Urol.  2008 Feb;179(2):516-22; discussion 522. (2008) Abstract

Weinrich SP, Seger RE, Rao GS, Chan EC, Hamm RM, Godley PA, Moul JW, Powell IJ, Chodak GW, Taylor KL, Weinrich MC. A decision aid for teaching limitations of prostate cancer screening. J Natl Black Nurses Assoc. 2008 Jul;19(1):1-11. (2008) Abstract

Schroeck FR, de Sousa CA, Kalman RA, Kalia MS, Pierre SA, Haleblian GE, Sun L, Moul JW, Albala DM. Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate. Urology. 2008 Apr;71(4):597-601. (2008) Abstract

Schroeck FR, Sun L, Freedland SJ, Jayachandran J, Robertson CN, Moul JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008;11(4):371-6. (2008) Abstract

Schroeck FR, Sun L, Freedland SJ, Albala DM, Mouraviev V, Polascik TJ, Moul JW. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. BJU Int. 2008 Jul;102(1):28-32. (2008) Abstract

Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ, Robertson CN, Tewari AK, Moul JW. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008 Oct;54(4):785-93. (2008) Abstract

Schroeck FR, Donatucci CF, Smathers EC, Sun L, Albala DM, Polascik TJ, Moul JW, Krupski TL. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008 Nov 15;113(10):2687-94. (2008) Abstract

Scales CD Jr, Antonelli J, Curtis LH, Schulman KA, Moul JW. Prostate-specific antigen screening among young men in the United States. Cancer. 2008 Sep 15;113(6):1315-23. (2008) Abstract

Rampersaud EN, Sun L, Moul JW, Madden J, Freedland SJ. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. J Urol. 2008 Aug;180(2):571-6; discussion 576. (2008) Abstract

Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate. 2008 Sep 15;68(13):1380-6. (2008) Abstract

Mouraviev V, Broadwater G, Sun L, Mayes JM, Moul JW, Polascik TJ. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years? Urology. 2008 Jun;71(6):1020-3. (2008) Abstract

Moul JW. Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Eur Urol. 2008 Jul;54(1):232-3. (2008) Abstract

Moul JW. Report from Durham. Prostate Cancer Prostatic Dis. 2008;11(3):211. (2008) Abstract

Moul JW. Report from Durham. Prostate Cancer Prostatic Dis. 2008;11(1):1. (2008) Abstract

Moul JW. Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients. Brachytherapy. 2008 Oct-Dec;7(4):277-9; discussion 284-5. (2008) Abstract

Moul JW. Are we overtreating prostate cancer? J Urol. 2008 Dec;180(6):2299-300. (2008) Abstract

Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2008 May;179(5 Suppl):S53-9. (2008) Abstract

Isariyawongse BK, Sun L, Bañez LL, Robertson C, Polascik TJ, Maloney K, Donatucci C, Albala D, Mouraviev V, Madden JF, Moul JW. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology. 2008 Oct;72(4):882-6. (2008) Abstract

Habib AS, White WD, El Gasim MA, Saleh G, Polascik TJ, Moul JW, Gan TJ. Transdermal nicotine for analgesia after radical retropubic prostatectomy. Anesth Analg. 2008 Sep;107(3):999-1004. (2008) Abstract

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int. 2008 Sep;102(8):969-74. (2008) Abstract

Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87. (2008) Abstract

Tseng TY, Cancel QV, Fesperman SF, Kuebler HR, Sun L, Robertson CN, Polascik TJ, Moul JW, Vieweg J, Albala DM, Dahm P. The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. J Urol. 2007 Apr;177(4):1318-23. (2007) Abstract

Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, . Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun;177(6):2106-31. (2007) Abstract

Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D, Polascik TJ. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int. 2007 Jan 22. (2007) Abstract

Scales CD Jr, Moul JW, Curtis LH, Elkin EP, Hughes ME, Carroll PR, . Prostate cancer in the Baby Boomer generation: results from CaPSURE. Urology. 2007 Dec;70(6):1162-7. (2007) Abstract

Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Dahm P, Moul JW. Relationship between body mass index and prostate cancer screening in the United States. J Urol. 2007 Feb;177(2):493-8. (2007) Abstract

Robinson MR, Moul JW. Novel techniques for the treatment of localized prostate cancer: evidence of efficacy? Curr Urol Rep. 2007 May;8(3):203-10. (2007) Abstract

Nosnik IP, Gan TJ, Moul JW. Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer? Expert Rev Anticancer Ther. 2007 Sep;7(9):1309-17. (2007) Abstract

Mouraviev V, Sun L, Madden JF, Mayes JM, Moul JW, Polascik TJ. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology. 2007 Dec;70(6):1141-5. (2007) Abstract

Mouraviev V, Nosnik I, Sun L, Robertson CN, Walther P, Albala D, Moul JW, Polascik TJ. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007 Feb;69(2):311-4. (2007) Abstract

Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007 Aug 15;110(4):906-10. (2007) Abstract

Moul JW. Timely diagnosis of testicular cancer. Urol Clin North Am. 2007 May;34(2):109-17; abstract vii. (2007) Abstract

Moul JW. Report from durham. Prostate Cancer Prostatic Dis. 2007;10(1):1. (2007) Abstract

Moul JW, Sun L, Hotaling JM, Fitzsimons NJ, Polascik TJ, Robertson CN, Dahm P, Anscher MS, Mouraviev V, Pappas PA, Albala DM. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol. 2007 Feb;177(2):499-503; discussion 503-4. (2007) Abstract

Moul JW, Bañez LL, Freedland SJ. Rising PSA in nonmetastatic prostate cancer. Oncology (Williston Park). 2007 Nov;21(12):1436-45; discussion 1449, 1452, 1454. (2007) Abstract

Freedland SJ, Moul JW. Prostate specific antigen recurrence after definitive therapy. J Urol. 2007 Jun;177(6):1985-91. (2007) Abstract

Fitzsimons NJ, Sun LL, Dahm P, Moul JW, Madden J, Gan TJ, Freedland SJ. A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. Urology. 2007 Dec;70(6):1146-51. (2007) Abstract

Fitzsimons NJ, Sun L, Moul JW. Medical technologies for the diagnosis of prostate cancer. Expert Rev Med Devices. 2007 Mar;4(2):227-39. (2007) Abstract

D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 2007 Jul 1;110(1):56-61. (2007) Abstract

Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007 Feb;177(2):540-5. (2007) Abstract

Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus S, Liebert M, Moul JW, Tangen C, Thrasher JB, Thompson I, . Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007 Aug;178(2):597-601. (2007) Abstract

Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007 Nov 21;298(19):2275-80. (2007) Abstract

Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(1):56-61. (2006) Abstract

Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(1):56-61. (2006) Abstract

Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(1):56-61. (2006) Abstract

Tseng TY, Sevilla DW, Moul JW, Maloney KE. Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. Prostate Cancer Prostatic Dis. 2006;9(2):195-7. (2006) Abstract

Tseng TY, Sevilla DW, Moul JW, Maloney KE. Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. Prostate Cancer Prostatic Dis. 2006;9(2):195-7. (2006) Abstract

Tseng TY, Sevilla DW, Moul JW, Maloney KE. Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. Prostate Cancer Prostatic Dis. 2006;9(2):195-7. (2006) Abstract

Sun M, Srikantan V, Ma L, Li J, Zhang W, Petrovics G, Makarem M, Strovel JW, Horrigan SG, Augustus M, Sesterhenn IA, Moul JW, Chandrasekharappa S, Zou Z, Srivastava S. Characterization of frequently deleted 6q locus in prostate cancer. DNA Cell Biol. 2006 Nov;25(11):597-607. (2006) Abstract

Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Albala DM, Moul JW. Prostate specific antigen testing in men older than 75 years in the United States. J Urol. 2006 Aug;176(2):511-4. (2006) Abstract

Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Albala DM, Moul JW. Prostate specific antigen testing in men older than 75 years in the United States. J Urol. 2006 Aug;176(2):511-4. (2006) Abstract

Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Albala DM, Moul JW. Prostate specific antigen testing in men older than 75 years in the United States. J Urol. 2006 Aug;176(2):511-4. (2006) Abstract

Moul JW. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Curr Pharm Des. 2006;12(7):785-98. (2006) Abstract

Moul JW. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Curr Pharm Des. 2006;12(7):785-98. (2006) Abstract

Moul JW. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Curr Pharm Des. 2006;12(7):785-98. (2006) Abstract

Moul JW. Report from durham. Prostate Cancer Prostatic Dis. 2006;9(3):199. (2006) Abstract

Moul JW. Prostate cancer. Curr Opin Urol. 2006 May;16(3):121-2. (2006) Abstract

Moul JW. Prostate cancer. Curr Opin Urol. 2006 May;16(3):121-2. (2006) Abstract

Moul JW. Prostate cancer. Curr Opin Urol. 2006 May;16(3):121-2. (2006) Abstract

Moul JW, Ward JF. Management of the Patient with a Rising PSA Alone. Hematol Oncol Clin North Am. 2006 Aug;20(4):897-908. (2006) Abstract

Moul JW, Ward JF. Management of the Patient with a Rising PSA Alone. Hematol Oncol Clin North Am. 2006 Aug;20(4):897-908. (2006) Abstract

Moul JW, Ward JF. Management of the Patient with a Rising PSA Alone. Hematol Oncol Clin North Am. 2006 Aug;20(4):897-908. (2006) Abstract

Merseburger AS, Hennenlotter J, Simon P, Müller CC, Kühs U, Knüchel-Clarke R, Moul JW, Stenzl A, Kuczyk MA. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep. 2006 Jul;16(1):79-83. (2006) Abstract

Merseburger AS, Hennenlotter J, Simon P, Müller CC, Kühs U, Knüchel-Clarke R, Moul JW, Stenzl A, Kuczyk MA. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep. 2006 Jul;16(1):79-83. (2006) Abstract

Merseburger AS, Hennenlotter J, Simon P, Müller CC, Kühs U, Knüchel-Clarke R, Moul JW, Stenzl A, Kuczyk MA. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep. 2006 Jul;16(1):79-83. (2006) Abstract

Lee WR, Moul JW. Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy? Nat Clin Pract Oncol. 2006 Oct;3(10):534-5. (2006) Abstract

Freedland SJ, Krupski TL, Moul JW. Update on outcomes research databases in prostate cancer 2006.  Curr Opin Urol.  2006 May;16(3):168-72. (2006) Abstract

Freedland SJ, Krupski TL, Moul JW. Update on outcomes research databases in prostate cancer 2006. Curr Opin Urol. 2006 May;16(3):168-72. (2006) Abstract

Freedland SJ, Krupski TL, Moul JW. Update on outcomes research databases in prostate cancer 2006. Curr Opin Urol. 2006 May;16(3):168-72. (2006) Abstract

Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006 Aug;68(2):342-7. (2006) Abstract

Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006 Aug;68(2):342-7. (2006) Abstract

Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006 Aug;68(2):342-7. (2006) Abstract

Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis. 2006 Aug 1. (2006) Abstract

Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis. 2006 Aug 1. (2006) Abstract

Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis. 2006 Aug 1. (2006) Abstract

Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005 Oct 1;23(28):6992-8. (2005) Abstract

Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005 Oct 1;23(28):6992-8. (2005) Abstract

Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005 Oct 1;23(28):6992-8. (2005) Abstract

Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer. 2005 Jun;4(1):38-44. (2005) Abstract

Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer. 2005 Jun;4(1):38-44. (2005) Abstract

Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer. 2005 Jun;4(1):38-44. (2005) Abstract

Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol. 2005 Apr;2(4):174-82. (2005) Abstract

Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol. 2005 Apr;2(4):174-82. (2005) Abstract

Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol. 2005 Apr;2(4):174-82. (2005) Abstract

Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May;15(3):187-95. (2005) Abstract

Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May;15(3):187-95. (2005) Abstract

Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May;15(3):187-95. (2005) Abstract

Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May;15(3):181-6. (2005) Abstract

Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May;15(3):181-6. (2005) Abstract

Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May;15(3):181-6. (2005) Abstract

Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005 Sep 20;23(27):6556-60. (2005) Abstract

Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005 Sep 20;23(27):6556-60. (2005) Abstract

Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005 Sep 20;23(27):6556-60. (2005) Abstract

Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem. 2005 Jan;51(1):102-12. (2005) Abstract

Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem. 2005 Jan;51(1):102-12. (2005) Abstract

Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem. 2005 Jan;51(1):102-12. (2005) Abstract

Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005 May 26;24(23):3847-52. (2005) Abstract

Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005 May 26;24(23):3847-52. (2005) Abstract

Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005 May 26;24(23):3847-52. (2005) Abstract

Moul JW. Screening for prostate cancer in military populations. Mil Med. 2005 Nov;170(11):905-14. (2005) Abstract

Moul JW. Screening for prostate cancer in military populations. Mil Med. 2005 Nov;170(11):905-14. (2005) Abstract

Moul JW. Screening for prostate cancer in military populations. Mil Med. 2005 Nov;170(11):905-14. (2005) Abstract

Moul JW, Zlotta AR. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. BJU Int. 2005 Feb;95(3):285-90. (2005) Abstract

Moul JW, Zlotta AR. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. BJU Int. 2005 Feb;95(3):285-90. (2005) Abstract

Moul JW, Zlotta AR. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. BJU Int. 2005 Feb;95(3):285-90. (2005) Abstract

Moul JW, Saad F. Low-risk prostate cancer patient: active treatment. Can J Urol. 2005 Jun;12 Suppl 2:25-7. (2005) Abstract

Moul JW, Saad F. Low-risk prostate cancer patient: active treatment. Can J Urol. 2005 Jun;12 Suppl 2:25-7. (2005) Abstract

Moul JW, Saad F. Low-risk prostate cancer patient: active treatment. Can J Urol. 2005 Jun;12 Suppl 2:25-7. (2005) Abstract

Gu Y, Kim KH, Ko D, Srivastava S, Moul JW, McLeod DG, Rhim JS. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Res. 2005 Jan-Feb;25(1A):1-8. (2005) Abstract

Gu Y, Kim KH, Ko D, Srivastava S, Moul JW, McLeod DG, Rhim JS. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Res. 2005 Jan-Feb;25(1A):1-8. (2005) Abstract

Gu Y, Kim KH, Ko D, Srivastava S, Moul JW, McLeod DG, Rhim JS. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Res. 2005 Jan-Feb;25(1A):1-8. (2005) Abstract

Dahm P, Yang BK, Salmen CR, Moul JW, Gan TJ. Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. J Urol. 2005 Jul;174(1):131-4. (2005) Abstract

Dahm P, Yang BK, Salmen CR, Moul JW, Gan TJ. Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. J Urol. 2005 Jul;174(1):131-4. (2005) Abstract

Dahm P, Yang BK, Salmen CR, Moul JW, Gan TJ. Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. J Urol. 2005 Jul;174(1):131-4. (2005) Abstract

Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10;23(32):8146-51. (2005) Abstract

Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10;23(32):8146-51. (2005) Abstract

Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10;23(32):8146-51. (2005) Abstract

Brassell SA, Kao TC, Sun L, Moul JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005 Dec;66(6):1229-33. (2005) Abstract

Brassell SA, Kao TC, Sun L, Moul JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005 Dec;66(6):1229-33. (2005) Abstract

Brassell SA, Kao TC, Sun L, Moul JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005 Dec;66(6):1229-33. (2005) Abstract

Bañez LL, Srivastava S, Moul JW. Proteomics in prostate cancer. Curr Opin Urol. 2005 May;15(3):151-6. (2005) Abstract

Bañez LL, Srivastava S, Moul JW. Proteomics in prostate cancer. Curr Opin Urol. 2005 May;15(3):151-6. (2005) Abstract

Bañez LL, Srivastava S, Moul JW. Proteomics in prostate cancer. Curr Opin Urol. 2005 May;15(3):151-6. (2005) Abstract

Wu H, Sun L, Moul JW, Wu HY, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol. 2004 Mar;171(3):1111-6. (2004) Abstract

Wu H, Sun L, Moul JW, Wu HY, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol. 2004 Mar;171(3):1111-6. (2004) Abstract

Wu H, Sun L, Moul JW, Wu HY, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol. 2004 Mar;171(3):1111-6. (2004) Abstract

Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan IA, Shrivasta S, McLeod DG, Moul JW, Peoples GE. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. Int J Oncol. 2004 Dec;25(6):1769-80. (2004) Abstract

Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan IA, Shrivasta S, McLeod DG, Moul JW, Peoples GE. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. Int J Oncol. 2004 Dec;25(6):1769-80. (2004) Abstract

Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan IA, Shrivasta S, McLeod DG, Moul JW, Peoples GE. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. Int J Oncol. 2004 Dec;25(6):1769-80. (2004) Abstract

Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol. 2004 Jul;24(4):449-61. (2004) Abstract

Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol. 2004 Jul;24(4):449-61. (2004) Abstract

Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol. 2004 Jul;24(4):449-61. (2004) Abstract

Shen D, Lao Z, Zeng J, Zhang W, Sesterhenn IA, Sun L, Moul JW, Herskovits EH, Fichtinger G, Davatzikos C. Optimized prostate biopsy via a statistical atlas of cancer spatial distribution. Med Image Anal. 2004 Jun;8(2):139-50. (2004) Abstract

Shen D, Lao Z, Zeng J, Zhang W, Sesterhenn IA, Sun L, Moul JW, Herskovits EH, Fichtinger G, Davatzikos C. Optimized prostate biopsy via a statistical atlas of cancer spatial distribution. Med Image Anal. 2004 Jun;8(2):139-50. (2004) Abstract

Shen D, Lao Z, Zeng J, Zhang W, Sesterhenn IA, Sun L, Moul JW, Herskovits EH, Fichtinger G, Davatzikos C. Optimized prostate biopsy via a statistical atlas of cancer spatial distribution. Med Image Anal. 2004 Jun;8(2):139-50. (2004) Abstract

Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, Fahey A. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004 Feb;19(2):146-55. (2004) Abstract

Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, Fahey A. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004 Feb;19(2):146-55. (2004) Abstract

Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, Fahey A. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004 Feb;19(2):146-55. (2004) Abstract

Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 1;22(3):537-56. (2004) Abstract

Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 1;22(3):537-56. (2004) Abstract

Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 1;22(3):537-56. (2004) Abstract

Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW, Srivastava S. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004 Jan 15;23(2):605-11. (2004) Abstract

Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW, Srivastava S. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004 Jan 15;23(2):605-11. (2004) Abstract

Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW, Srivastava S. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004 Jan 15;23(2):605-11. (2004) Abstract

Petroski RA, Warlick WB, Herring J, Donahue TF, Sun L, Smith CV, Connelly RR, McLeod DG, Moul JW. External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence. Prostate Cancer Prostatic Dis. 2004;7(2):170-7. (2004) Abstract

Petroski RA, Warlick WB, Herring J, Donahue TF, Sun L, Smith CV, Connelly RR, McLeod DG, Moul JW. External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence. Prostate Cancer Prostatic Dis. 2004;7(2):170-7. (2004) Abstract

Petroski RA, Warlick WB, Herring J, Donahue TF, Sun L, Smith CV, Connelly RR, McLeod DG, Moul JW. External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence. Prostate Cancer Prostatic Dis. 2004;7(2):170-7. (2004) Abstract

Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004 Jun;171(6 Pt 1):2250-4. (2004) Abstract

Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004 Jun;171(6 Pt 1):2250-4. (2004) Abstract

Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004 Jun;171(6 Pt 1):2250-4. (2004) Abstract

Moul JW. The evolving definition of advanced prostate cancer. Rev Urol. 2004;6 Suppl 8:S10-7. (2004) Abstract

Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004 Mar;171(3):1141-7. (2004) Abstract

Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004 Mar;171(3):1141-7. (2004) Abstract

Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004 Mar;171(3):1141-7. (2004) Abstract

Moul JW, Chodak G. Combination hormonal therapy: a reassessment within advanced prostate cancer. Prostate Cancer Prostatic Dis. 2004 Sep;7 Suppl 1:S2-7. (2004) Abstract

Moul JW, Chodak G. Combination hormonal therapy: a reassessment within advanced prostate cancer. Prostate Cancer Prostatic Dis. 2004 Sep;7 Suppl 1:S2-7. (2004) Abstract

Moul JW, Chodak G. Combination hormonal therapy: a reassessment within advanced prostate cancer. Prostate Cancer Prostatic Dis. 2004 Sep;7 Suppl 1:S2-7. (2004) Abstract

Kirby R, Moul JW. Is the PSA test useless? Prostate Cancer Prostatic Dis. 2004;7(4):271-2. (2004) Abstract

Kirby R, Moul JW. Is the PSA test useless? Prostate Cancer Prostatic Dis. 2004;7(4):271-2. (2004) Abstract

Kirby R, Moul JW. Is the PSA test useless? Prostate Cancer Prostatic Dis. 2004;7(4):271-2. (2004) Abstract

Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava S, Arnstein P, Rhim JS. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. Int J Oncol. 2004 Oct;25(4):1057-64. (2004) Abstract

Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava S, Arnstein P, Rhim JS. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. Int J Oncol. 2004 Oct;25(4):1057-64. (2004) Abstract

Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava S, Arnstein P, Rhim JS. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. Int J Oncol. 2004 Oct;25(4):1057-64. (2004) Abstract

Gilligan T, Manola J, Sartor O, Weinrich SP, Moul JW, Kantoff PW. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer. 2004 Sep;3(2):98-103. (2004) Abstract

Gilligan T, Manola J, Sartor O, Weinrich SP, Moul JW, Kantoff PW. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer. 2004 Sep;3(2):98-103. (2004) Abstract

Gilligan T, Manola J, Sartor O, Weinrich SP, Moul JW, Kantoff PW. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer. 2004 Sep;3(2):98-103. (2004) Abstract

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst. 2004 Apr 7;96(7):509-15. (2004) Abstract

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst. 2004 Apr 7;96(7):509-15. (2004) Abstract

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst. 2004 Apr 7;96(7):509-15. (2004) Abstract

Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004 Feb 1;22(3):439-45. (2004) Abstract

Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004 Feb 1;22(3):439-45. (2004) Abstract

Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004 Feb 1;22(3):439-45. (2004) Abstract